Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

PURE Bioscience (PURE) had Revenue of $0.49M for the most recently reported fiscal quarter, ending 2025-04-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-04-30

Income Statement Financials
Revenue	$0.49M
Net Income	$-0.58M
Cost of Goods Sold	$0.21M
Gross Profit	$0.28M
Operating Expenses	$1.07M
Operating Income	$-0.58M
Non-Operating Income/Expense	$0.00M
Pre-Tax Income	$-0.58M
Normalized Pre-Tax Income	$-0.58M
Income after Taxes	$-0.58M
Income from Continuous Operations	$-0.58M
Consolidated Net Income/Loss	$-0.58M
Normalized Income after Taxes	$-0.58M
EBIT	$-0.58M
EBITDA	$-0.58M
Weighted-Average Shares Outstanding (Basic)	111.86M
Weighted-Average Shares Outstanding (Diluted)	111.86M
Earnings per Share (EPS) (Basic)	$-0.01
Earnings per Share (EPS) (Diluted)	$-0.01
Balance Sheet Financials
Current Assets	$1.05M
Property, Plant, and Equipment	$0.01M
Long-Term Assets	$0.01M
Total Assets	$1.06M
Current Liabilities	$0.97M
Long-Term Debt	$4.90M
Long-Term Liabilities	$4.90M
Total Liabilities	$5.87M
Common Equity	$-4.81M
Tangible Shareholders Equity	$-4.81M
Shareholders Equity	$-4.81M
Common Shares Outstanding	111.86M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-1.56M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$1.75M
Beginning Cash	$0.42M
End Cash	$0.61M
Increase/Decrease in Cash	$0.19M
Stock-Based Compensation	$0.12M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	57.64
Debt to Equity Ratio	-1.02
Gross Margin	57.64%
Operating Margin	-118.94%
EBIT Margin	-118.94%
EBITDA Margin	--
Pre-Tax Profit Margin	-118.13%
Profit Margin	-118.13%
Free Cash Flow	$-1.56M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.46
Inventory Turnover	1.59
Receiveable Turnover	1.71
Days Sales in Receivables	52.61
Return on Equity	12.05%
Return on Tangible Equity	12.05%
Return on Assets	-54.87%
Return on Investments	-682.35%
Book Value Per Share	$-0.04
Free Cash Flow per Share	$-0.01
Operating Cash Flow per Share	$-0.01

Data from Zacks Investment Research, Inc.